These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18466425)

  • 1. Current status and impact of CMV prevention following pediatric organ transplantation.
    Allen UD
    Pediatr Transplant; 2008 Jun; 12(4):389-92. PubMed ID: 18466425
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention and management of cytomegalovirus infection in solid-organ transplantation.
    Mwintshi K; Brennan DC
    Expert Rev Anti Infect Ther; 2007 Apr; 5(2):295-304. PubMed ID: 17402844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of cytomegalovirus following solid organ transplantation: a literature review.
    Kowalsky S; Arnon R; Posada R
    Pediatr Transplant; 2013 Sep; 17(6):499-509. PubMed ID: 23890075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed occurrence of cytomegalovirus disease in organ transplant recipients receiving antiviral prophylaxis: are we winning the battle only to lose the war?
    Singh N
    Eur J Clin Microbiol Infect Dis; 2002 Sep; 21(9):643-6. PubMed ID: 12373496
    [No Abstract]   [Full Text] [Related]  

  • 5. Valganciclovir: therapeutic role in pediatric solid organ transplant recipients.
    Yu MA; Park JM
    Expert Opin Pharmacother; 2013 Apr; 14(6):807-15. PubMed ID: 23469871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preemptive versus prophylactic approaches in the management of cytomegalovirus disease in solid organ transplant recipients: what we know and what we do not know.
    Meylan PR; Pascual M
    Clin Infect Dis; 2006 Oct; 43(7):881-3. PubMed ID: 16941369
    [No Abstract]   [Full Text] [Related]  

  • 7. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies.
    Small LN; Lau J; Snydman DR
    Clin Infect Dis; 2006 Oct; 43(7):869-80. PubMed ID: 16941368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.
    Freeman RB
    Expert Opin Pharmacother; 2004 Sep; 5(9):2007-16. PubMed ID: 15330737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus infection in organ transplant recipients.
    Hibberd PL; Snydman DR
    Infect Dis Clin North Am; 1995 Dec; 9(4):863-77. PubMed ID: 8747770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
    Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
    J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation.
    Wagner JA; Ross H; Hunt S; Gamberg P; Valantine H; Merigan TC; Stinson EB
    Transplantation; 1995 Dec; 60(12):1473-7. PubMed ID: 8545877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Summary of the British Transplantation Society Guidelines for the Prevention and Management of CMV Disease After Solid Organ Transplantation.
    Andrews PA; Emery VC; Newstead C
    Transplantation; 2011 Dec; 92(11):1181-7. PubMed ID: 22002346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy.
    Reischig T
    Expert Rev Anti Infect Ther; 2012 Jan; 10(1):51-61. PubMed ID: 22149614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cytomegalovirus infection after solid-organ transplantation, its risk factors, direct and indirect effects and prevention strategies].
    Varga M; Remport A; Czebe K; Péter A; Toronyi E; Sárváry E; Fehérvári I; Sulyok B; Járay J
    Orv Hetil; 2008 Mar; 149(12):551-8. PubMed ID: 18343771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
    Ahsan N; Holman MJ; Yang HC
    Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients.
    Boivin G; Goyette N; Gilbert C; Humar A; Covington E
    Transpl Infect Dis; 2005; 7(3-4):166-70. PubMed ID: 16390409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term care after hematopoietic-cell transplantation in adults.
    Boeckh M; Nichols WG; Marr KA
    N Engl J Med; 2002 Nov; 347(20):1625-6; author reply 1625-6. PubMed ID: 12432056
    [No Abstract]   [Full Text] [Related]  

  • 18. Oral ganciclovir usage for cytomegalovirus prophylaxis in organ transplant recipients: is emergence of resistance imminent?
    Singh N; Yu VL
    Dig Dis Sci; 1998 Jun; 43(6):1190-2. PubMed ID: 9635606
    [No Abstract]   [Full Text] [Related]  

  • 19. Cytomegalovirus in transplantation - challenging the status quo.
    Fishman JA; Emery V; Freeman R; Pascual M; Rostaing L; Schlitt HJ; Sgarabotto D; Torre-Cisneros J; Uknis ME
    Clin Transplant; 2007; 21(2):149-58. PubMed ID: 17425738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Organ transplantation infection and its prevention and treatment].
    Wang E; Liu Y
    Zhonghua Nei Ke Za Zhi; 1996 May; 35(5):350-2. PubMed ID: 9387619
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.